ArticleiScience2026
Deep-learning-based artificial intelligence approaches for grading and progression prediction of clear cell renal cell carcinoma.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The grading classification of clear cell renal cell carcinoma (CCRCC) is a crucial prognostic factor. However, manual observation can lead to subjective and inconsistent diagnoses. In this study, we aimed to develop a deep-learning-based grading system for CCRCC using whole-slide image (WSI) and to predict disease progression. A total of 305 CCRCC cases were used to develop the renal cell carcinoma artificial intelligence diagnosis (RCCAID) model for grading (188 training, 47 verification, and 70 testing cases) and the renal cell carcinoma artificial intelligence prognostic (RCCAIP) progression prediction model (288 cases). Progression was defined as the presence of distant and/or lymph node metastasis. Xception, ResNet50, and Inception V3 were employed. Model performance was assessed via confusion matrix, receiver operator characteristic curve (ROC) curve, and classification map. RCCAID achieved area under the curve (AUC) values of 0.987 (internal), 0.996 (in-house), and 0.967 (external). The quadratic weighted Cohen's kappa was 0.864, comparable to senior pathologists (0.871). RCCAIP achieved an AUC of 0.94 for progression prediction. Higher grades correlated with worse prognosis. RCCAID can accurately grade CCRCC in whole-slide images, and RCCAIP is effective in progression prediction, even for low-grade tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.